However, with advancements in diabetes treatment, more effective therapies have emerged for T2DM patients with these comorbidities, which has led to repositioning the role of DPP-4 inhibitors, primarily in T2DM patients without these conditions. The gene discussed is DPP4; the disease is diabetes mellitus.